Access Bio Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Young-Ho Choi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares
Nov 13
Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking
Aug 07Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem
Mar 26Is Access Bio (KOSDAQ:950130) A Risky Investment?
Mar 25If You Had Bought Access Bio (KOSDAQ:950130) Shares A Year Ago You'd Have Earned 740% Returns
Feb 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -₩16b |
| Mar 31 2024 | n/a | n/a | -₩42b |
| Dec 31 2023 | n/a | n/a | -₩3b |
| Sep 30 2023 | n/a | n/a | ₩7b |
| Jun 30 2023 | n/a | n/a | -₩2b |
| Mar 31 2023 | n/a | n/a | ₩100b |
| Dec 31 2022 | n/a | n/a | ₩347b |
| Sep 30 2022 | n/a | n/a | ₩418b |
| Jun 30 2022 | n/a | n/a | ₩453b |
| Mar 31 2022 | n/a | n/a | ₩356b |
| Dec 31 2021 | n/a | n/a | ₩190b |
| Sep 30 2021 | n/a | n/a | ₩168b |
| Jun 30 2021 | n/a | n/a | ₩151b |
| Mar 31 2021 | n/a | n/a | ₩172b |
| Dec 31 2020 | ₩1b | ₩326m | ₩48b |
Compensation vs Market: Insufficient data to establish whether Young-Ho's total compensation is reasonable compared to companies of similar size in the KR market.
Compensation vs Earnings: Insufficient data to compare Young-Ho's compensation with company performance.
CEO
Young-Ho Choi (60 yo)
no data
Tenure
₩1,253,201,612
Compensation
Mr. Young-Ho Choi serves as Chief Executive Officer and President of Access Bio, Inc. Mr. Choi has R&D and managements experience for IVD field. Mr. Choi is an Oak Ridge Conference Outstanding Awardee for...